According to Brazilian media outlet Conselho, the Brazilian National Health Surveillance Agency (Anvisa) is currently soliciting public opinions on a new draft regulation for e-cigarettes. The consultation and open voting activities will conclude on February 9, 2024.
Brazil's health regulatory agency, Anvisa, approved a proposal for Consultative Public Voting (CP) in December 2023. The proposal, identified as number 1.222/2023, primarily addresses regulations for electronic cigarette devices (DEFs). This new resolution will replace the existing regulations that have been enforced since 2009.
The main points of this proposal include the continued prohibition of the production, import, sale, distribution, storage, and transportation of e-cigarettes, including all types of e-cigarettes. It also explicitly states that any form of public promotion for these products is prohibited, regardless of whether it is targeted towards consumers.
The Brazilian National Health Council (CNS) believes that the proposal by Anvisa is crucial and will contribute to improving the health and well-being of the Brazilian people. They support the revision of current regulations and consider this adjustment to align with the recommendations of the World Health Organization's Framework Convention on Tobacco Control and scientific evidence.
All individuals concerned about this matter have the opportunity to participate and provide feedback by February 9, 2024. Participants can provide simplified feedback by using the dedicated electronic form available on the official Anvisa website, indicating their support for the proposal, or they can provide detailed comments on each clause of the proposal.
The objective of Anvisa's public consultation is to make decisions regarding specific regulations based on solid evidence. Its main goal is to gather critical and well-founded evaluations of the suggested regulations from different sectors of society. Once all suggestions have been received, Anvisa will review all feedback and release a report on the public consultation on its official website.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
